Effect of pravastatin on left ventricular mass by activation of myocardial KATP channels in hypercholesterolemic rabbits

Atherosclerosis

Volumn 176, Issue 2, 2004, Pages 273-278

  Lee, Tsung Ming ^a   Lin, Mei Shu ^b   Chou, Tsai Fwu ^c   Tsai, Chang Her ^b   Chang, Nen Chung ^d  

^a CHI MEI FOUNDATION HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c JEN AI HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ATP sensitive potassium channels; Hyperlipidemia; Pravastatin; Ventricular mass

Indexed keywords

GLIBENCLAMIDE; NICORANDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; PRAVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATTENUATION; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEEDING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE; HEMODYNAMICS; HYPERCHOLESTEROLEMIA; MALE; MORPHOLOGY; MUSCLE CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RABBIT; RANDOMIZATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTICHOLESTEREMIC AGENTS; DISEASE MODELS, ANIMAL; HEART; HYPERCHOLESTEROLEMIA; HYPERTROPHY, LEFT VENTRICULAR; MALE; POTASSIUM CHANNELS; PRAVASTATIN; RABBITS;

EID: 5644245068     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.06.005     Document Type: Article

References (28)

1. 2α formation. J. Cardiovasc. Pharmacol. 40:2002;868-874
2. Sundstrom J., Lind L., Vessby B., Andren B., Aro A., Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation. 103:2001;836-841
3. Castelli W.P., Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients of the Framingham Study. Am. J. Med. 80(Suppl. 2A):1986;23-32
4. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513
5. Saeed M., Watzinger N., Krombach G.A., Lund G.K., Wendland M.F., Chujo M., et al. Left ventricular remodeling after infarction: sequential MR imaging with oral nicorandil therapy in rat model. Radiology. 224:2002;830-837
6. Ueda Y., Kitakaze M., Komamura K., Minamino T., Asanuma H., Sato H., et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J. Am. Coll. Cardiol. 34:1999;2120-2125
7. Ren Y.J., Xu X.H., Zhong C.B., Feng N., Wang X.L. Hypercholesterolemia alters vascular functions and gene expression of potassium channels in rat aortic smooth muscle cells. Acta Pharmacol. Sin. 22:2001;274-278
8. Sanada S., Node K., Asanuma H., Ogita H., Takashima S., Minamino T., et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J. Am. Coll. Cardiol. 40:2002;991-997
9. Lee T.M., Su S.F., Tsai C.H. Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension. 40:2002;67-73
10. Lee T.M., Su S.F., Chou T.F., Tsai C.H. Effect of pravastatin on myocardial protection during coronary angioplasty and the role of adenosine. Am. J. Cardiol. 88:2001;1108-1113
11. Garnier-Raveaud S., Faury G., Mazenot C., Cand F., Godin-Ribuot D., Verdetti J. Highly protective effects of chronic oral administration of nicorandil on the heart of ageing rats. Clin. Exp. Pharmacol. Physiol. 29:2002;441-448
12. Abd Elaziz M.A., Al-Dhawailie A.A., Teckle A. The effect of stress on the pharmacokinetics and pharmacodynamics of glibenclamide in diabetic rats. Eur. J. Drug Metab. Pharmacokinet. 23:1998;371-376
13. Lee T.M., Chou T.F., Tsai C.H. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J. Mol. Cell Cardiol. 35:2003;1449-1459
14. ATP channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J. Am. Coll. Cardiol. 40:2002;1339-1346
15. Kawabata H., Ryomoto T., Ishikawa K. Role of cardiac ATP-sensitive K+ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts. Hypertens. Res. 24:2001;573-577
16. Glorioso N., Manunta P., Filigheddu F., Troffa C., Stella P., Barlassina C., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 34:1999;1281-1286
17. Muramatsu J., Kobayashi A., Hasegawa N., Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis. 130:1997;179-182
18. Belke D.D., Betuing S., Turtte M.J., Graveleau C., Young M.E., Pham M., et al. Insulin signaling coordinately regulates cardiac size, metabolism, and contractile protein isoform expression. J. Clin. Invest. 109:2002;629-639
19. Pang Y., Hunton D.L., Bounelis P., Marchase R.B. Hyperglycemia inhibits capacitative calcium entry and hypertrophy in neonatal cardiomyocytes. Diabetes. 51:2002;3461-3467
20. Lane H.A., Fernandez A., Lamb N.J., Thomas G. p70s6k function is essential for G1 progression. Nature. 63:1993;170-172
21. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108:2001;1429-1437
22. Hirayama H., Sugano M., Abe N., Yonemochi H., Makino N. Determination of left ventricular mass by echocardiography in normotensive diabetic patients. Jpn. Circ. J. 64:2000;921-924
23. Lee T.M., Chou T.F. Impairment of myocardial protection in type 2 diabetic patients. J. Clin. Endocrin. Metab. 88:2003;531-537
24. 2+ channel Pfugers. Arch. 434:1997;362-372
25. Schotborgh C.E., Wilde A.A.M. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients. Cardiovasc. Res. 34:1997;73-80
26. 2+ blockers prevent myocardial remodeling induced by chronic NO inhibition in rats. Hypertension. 41:2003;963-967
27. Leineweber K., Brandt K., Wludyka B., Beilfuss A., Ponicke K., Heinroth-Hoffmann I., et al. Ventricular hypertrophy plus neurohumoral activation is necessary to alter the cardiac β-adrenoceptor system in experimental heart failure. Circ. Res. 91:2002;1056-1062
28. ATP channels activated by 17β-estradiol on reperfusion arrhythmias and infarct sizes in canine hearts. J. Pharmacol. Exp. Ther. 301:2002;234-240